Literature DB >> 30993667

Ivermectin Dosing Strategy to Achieve Equivalent Exposure Coverage in Children and Adults.

Janneke M Brussee1,2,3, Jessica D Schulz1,2, Jean T Coulibaly1,2,4,5, Jennifer Keiser1,2, Marc Pfister2,3,6.   

Abstract

Ivermectin is a commonly used broad-spectrum antiparasitic drug, yet doses that produce consistent exposure coverage across age have not been characterized, and no data are available in children weighing < 15 kg. First, a population pharmacokinetic model is developed based on data from 200 children and 11 adults, treated with 100-600 μg/kg ivermectin. Second, model-based simulations are performed to identify a dosing strategy that achieves equivalent exposure coverage in children and adults. Median (90% confidence interval) clearance of 0.346 (0.12-0.73) L/hour/kg in pre-school-aged (2-5 years) children is similar to 0.352 (0.17-0.69) L/hour/kg in school-aged (6-12 years) children but higher than in adults (0.199 (0.10-0.31) L/hour/kg), resulting in significantly lower exposure in children following a 200 μg/kg dose. Simulations indicate that a dose increase to 300 and 250 μg/kg in children aged 2-5 and 6-12 years, respectively, will achieve equivalent ivermectin exposure coverage in children and adults.
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30993667     DOI: 10.1002/cpt.1456

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Pharmacometric Analysis of Tribendimidine Monotherapy and Combination Therapies To Achieve High Cure Rates in Patients with Hookworm Infections.

Authors:  Janneke M Brussee; Anna Neodo; Jessica D Schulz; Jean T Coulibaly; Marc Pfister; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 2.  Broadening the range of use cases for ivermectin - a review of the evidence.

Authors:  Christian Kositz; John Bradley; Harry Hutchins; Anna Last; Umberto D'Alessandro; Michael Marks
Journal:  Trans R Soc Trop Med Hyg       Date:  2022-03-02       Impact factor: 2.455

3.  A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?

Authors:  Podjanee Jittamala; Wuelton Monteiro; Menno R Smit; Belen Pedrique; Sabine Specht; Carlos J Chaccour; Céline Dard; Pascal Del Giudice; Virak Khieu; Annabel Maruani; Virgilio E Failoc-Rojas; Marimar Sáez-de-Ocariz; Antoni Soriano-Arandes; Jaime Piquero-Casals; Anne Faisant; Marie-Pierre Brenier-Pinchart; David Wimmersberger; Jean T Coulibaly; Jennifer Keiser; Franck Boralevi; Oliver Sokana; Michael Marks; Daniel Engelman; Lucia Romani; Andrew C Steer; Lorenz von Seidlein; Nicholas J White; Eli Harriss; Kasia Stepniewska; Georgina S Humphreys; Kalynn Kennon; Philippe J Guerin; Kevin C Kobylinski
Journal:  PLoS Negl Trop Dis       Date:  2021-03-17

4.  Optimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modeling.

Authors:  Daniela Hofmann; Cornelis Smit; Somphou Sayasone; Marc Pfister; Jennifer Keiser
Journal:  Clin Transl Sci       Date:  2021-12-09       Impact factor: 4.689

5.  Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with Strongyloides Stercoralis: Support for a Fixed-Dose Treatment Regimen.

Authors:  Cornelis Smit; Daniela Hofmann; Somphou Sayasone; Jennifer Keiser; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2021-07-23       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.